PBS updates

Sunitinib Sandoz (Sunitinib)

sunitinib 25 mg capsule, 28 · ORAL · PBS code 2959R

AUTHORITY_REQUIRED

What it costs

AU$919.06 PBS-determined price per 28 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2021-10-01.
  • • Repeats: 2.
  • • PBS program: GE.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Metastatic or unresectable, well-differentiated malignant pancreatic neuroendocrine tumour (pNET)


Initial treatment


Patient must be symptomatic (despite somatostatin analogues); or

Patient must have disease progression; AND

The treatment must be as monotherapy.

Disease progression must be documented in the patient's medical records.

Patients who have developed progressive disease with any of: (i) everolimus; (ii) cabozantinib are not eligible to receive PBS-subsidised treatment with sunitinib for this condition.

Patients who have developed intolerance with any of: (i) everolimus; (ii) cabozantinib of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised sunitinib.

Sponsor: Sandoz Pty Ltd ABN 60 075 449 553

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.